Royalty Pharma plc Files 2023 Annual Report on Form 10-K

TL;DR

<b>Royalty Pharma plc has filed its annual 10-K report for the fiscal year ending December 31, 2023, detailing its financial performance and business operations.</b>

AI Summary

Royalty Pharma plc (RPRX) filed a Annual Report (10-K) with the SEC on February 15, 2024. Royalty Pharma plc filed its 2023 Form 10-K on February 15, 2024. The filing covers the fiscal year ending December 31, 2023. The company's principal business is in Pharmaceutical Preparations (SIC 2834). Royalty Pharma plc is incorporated in X0 with its principal executive offices in New York, NY. The filing includes data related to various share classes (Common Class A, Common Class B, Class R Redeemable Stock) and royalty assets.

Why It Matters

For investors and stakeholders tracking Royalty Pharma plc, this filing contains several important signals. This 10-K filing provides a comprehensive overview of Royalty Pharma's financial health, operational activities, and strategic positioning for the past fiscal year, crucial for investors assessing its long-term value. The detailed financial statements and risk factors within the report offer insights into the company's revenue streams, asset base, and potential challenges, enabling informed investment decisions.

Risk Assessment

Risk Level: — Royalty Pharma plc shows moderate risk based on this filing. The company operates in the pharmaceutical sector, which is subject to significant regulatory oversight, patent expirations, and competitive pressures, as indicated by its SIC code and the nature of its business.

Analyst Insight

Investors should review the detailed financial statements and risk factors in the 10-K to understand Royalty Pharma's performance and outlook for the upcoming fiscal year.

Key Numbers

• 2023-12-31 — Fiscal Year End (Conformed period of report)
• 2024-02-15 — Filing Date (As of date)
• 001-39329 — SEC File Number (SEC file number)

Key Players & Entities

• Royalty Pharma plc (company) — Filer
• 2023 (date) — Fiscal year end
• 2024-02-15 (date) — Filing date
• New York, NY (location) — Business address
• 2834 (industry) — Standard Industrial Classification

FAQ

Industry Context

Royalty Pharma plc operates within the pharmaceutical preparations industry, a sector characterized by significant research and development, regulatory hurdles, and intellectual property considerations.

Regulatory Implications

Companies in the pharmaceutical sector are subject to stringent regulations from bodies like the FDA, impacting drug development, marketing, and pricing.

What Investors Should Do

1. Analyze the detailed financial statements within the 10-K for revenue trends, profitability, and asset composition.
2. Review the risk factors section to understand potential challenges and their impact on future performance.
3. Compare key financial metrics with previous years to identify performance trends and assess growth.

Key Dates

• 2023-12-31: Fiscal Year End — End of the reporting period for the 10-K.
• 2024-02-15: Filing Date — Date the 10-K was officially filed with the SEC.

Glossary

10-K

An annual report required by the U.S. Securities and Exchange Commission (SEC), which gives a comprehensive summary of a company's financial performance. (This is the primary document filed by Royalty Pharma plc to report its annual financial results and business activities.)

SIC Code 2834

Standard Industrial Classification code for Pharmaceutical Preparations. (Indicates Royalty Pharma plc's primary industry focus.)

Year-Over-Year Comparison

This filing represents the annual 10-K for the fiscal year ending December 31, 2023, providing a year-end summary compared to previous filings.

Key Financial Figures

• $0.0001 — ed Class A ordinary shares , par value $0.0001 RPRX The Nasdaq Stock Market LLC Sec
• $3.0 billion — pportunity set. In 2023, we generated $3.0 billion of Portfolio Receipts (as defined below
• $4.0 billion — actions with a total potential value of $4.0 billion. Portfolio Receipts is a key performanc
• $2.2 billion — garding Portfolio Receipts. We deployed $2.2 billion of cash to acquire royalties, milestone
• $1.1 — utical sales are projected to grow from $1.1 trillion in 2023 to $1.5 trillion in 20
• $1.5 — d to grow from $1.1 trillion in 2023 to $1.5 trillion in 2028, representing a compou
• $150 billion — ing to EvaluatePharma despite more than $150 billion in cumulative sales being lost to expec
• $1 — non-profit institutions will spend over $1 trillion in R&D, unprofitable biopharma
• $2 — harmaceutical companies will spend over $2 trillion in R&D. 2 Royalties play a
• $7.4 billion — for biopharmaceutical royalties reached $7.4 billion in transaction value in 2023, a greater
• $26.4 billion — ns with an aggregate announced value of $26.4 billion from 2012 through 2023, which represent
• $3.7 billion — mpetitor, which we believe has executed $3.7 billion of transactions, and represents an esti
• $500 million — ns with an aggregate value of more than $500 million each. We have executed 12 of these 15 t
• $17.0 billion — otal transaction value of approximately $17.0 billion of cash and an estimated market share o
• $1 billion — generated end-market sales of more than $1 billion in 2023, including six therapies that e

Filing Documents

• rprx-20231231.htm (10-K) — 2484KB
• rprx-20231231ex42.htm (EX-4.2) — 40KB
• rprx-20231231ex1021.htm (EX-10.21) — 1286KB
• rprx-20231231ex211.htm (EX-21.1) — 7KB
• rprx-20231231ex231.htm (EX-23.1) — 4KB
• rprx-20231231ex311.htm (EX-31.1) — 9KB
• rprx-20231231ex312.htm (EX-31.2) — 9KB
• rprx-20231231ex32.htm (EX-32) — 5KB
• rprx-20231231ex971.htm (EX-97.1) — 41KB
• rprx-20231231_g1.jpg (GRAPHIC) — 93KB
• rprx-20231231_g2.jpg (GRAPHIC) — 61KB
• rprx-20231231_g3.jpg (GRAPHIC) — 73KB
• rprx-20231231_g4.jpg (GRAPHIC) — 136KB
• 0001802768-24-000012.txt (&nbsp;) — 13271KB
• rprx-20231231.xsd (EX-101.SCH) — 71KB
• rprx-20231231_cal.xml (EX-101.CAL) — 99KB
• rprx-20231231_def.xml (EX-101.DEF) — 399KB
• rprx-20231231_lab.xml (EX-101.LAB) — 855KB
• rprx-20231231_pre.xml (EX-101.PRE) — 564KB
• rprx-20231231_htm.xml (XML) — 1655KB

Risk Factors

Item 1A. Risk Factors 14

Unresolved Staff Comments

Item 1B. Unresolved Staff Comments 42

Cybersecurit y

Item 1C. Cybersecurit y 42

Properties

Item 2. Properties 43

Legal Proceedings

Item 3. Legal Proceedings 43

Mine Safety Disclosures

Item 4. Mine Safety Disclosures 43 PART II Item 5. Market for the Registrant's Common Equity, Related Stockholder Matters, and Issuer Purchases of Equity Securities 43

[ Reserved ]

Item 6. [ Reserved ] 46

Management's Discussion and Analysis of Financial Condition and Results of Operations

Item 7. Management's Discussion and Analysis of Financial Condition and Results of Operations 46

Quantitative and Qualitative Disclosures About Market Risk

Item 7A. Quantitative and Qualitative Disclosures About Market Risk 72

Financial Statements and Supplementary Data

Item 8. Financial Statements and Supplementary Data 74

Changes in and Disagreements with Accountants on Accounting and Financial Disclosures

Item 9. Changes in and Disagreements with Accountants on Accounting and Financial Disclosures 111

Controls and Procedures

Item 9A. Controls and Procedures 111

Other Information

Item 9B. Other Information 112

Disclosure Regarding Foreign Jurisdictions That Prevent Inspections

Item 9C. Disclosure Regarding Foreign Jurisdictions That Prevent Inspections 112 PART III

Directors, Executive Officers and Corporate Governance

Item 10. Directors, Executive Officers and Corporate Governance 112

Executive Compensation

Item 11. Executive Compensation 112

Security Ownership of Certain Beneficial Owners and Management and Related Stockholder Matters

Item 12. Security Ownership of Certain Beneficial Owners and Management and Related Stockholder Matters 112

Certain Relationships and Related Transactions, and Director Independence

Item 13. Certain Relationships and Related Transactions, and Director Independence 112

Principal Accountant Fees and Services

Item 14. Principal Accountant Fees and Services 112 PART IV

Exhibits and Financial Statement Schedules

Item 15. Exhibits and Financial Statement Schedules 113

Form 10-K Summary

Item 16. Form 10-K Summary 115

Signatures

Signatures 115 Special Note Regarding Forward-Looking Statements This Annual Report on Form 10-K contains statements reflecting our views about our future performance that constitute "forward-looking statements" within the meaning of the Private Securities Litigation Reform Act of 1995. In some cases, you can identify these statements by forward-looking words such as "may," "might," "will," "should," "expects," "plans," "anticipates," "believes," "estimates," "target," "forecast," "guidance," "goal," "predicts," "project," "potential" or "continue," the negative of these terms and other comparable terminology. These forward-looking statements are not historical facts, but rather are based on current expectations, estimates and projections about us, our current and prospective assets, our industry, our beliefs and our assumptions. These statements are not guarantees of future performance and are subject to risks, uncertainties and other factors, some of which are beyond our control and difficult to predict and could cause actual results to differ materially from those expressed or forecasted in the forward-looking statements. There are important factors that could cause our actual results, level of activity, performance or achievements to differ materially from the results, level of activity, performance or achievements expressed or implied by the forward-looking statements. You should evaluate all forward-looking statements made in this Annual Report on Form 10-K in the context of the numerous risks outlined in Part I under Item 1A. under "Risk Factors" in this Annual Report on Form 10-K. These risks and uncertainties include factors related to, among other topics: sales risks of biopharmaceutical products on which we receive royalties; the ability of RP Management, LLC (the "Manager") to locate suitable assets for us to acquire; uncertainties related to the acquisition of interests in development-stage biopharmaceutical product candidates and our strategy

BUSINESS

Item 1. BUSINESS Overview We are the largest buyer of biopharmaceutical royalties and a leading funder of innovation across the biopharmaceutical industry. Since our founding in 1996, we have been pioneers in the royalty market, collaborating with innovators from academic institutions, research hospitals and not-for-profits through small and mid-cap biotechnology companies to leading global pharmaceutical companies. We have assembled a portfolio of royalties which entitles us to payments based directly on the top-line sales of many of the industry's leading therapies, which includes royalties on more than 35 commercial products, including Vertex's Trikafta, GSK's Trelegy, Roche's Evrysdi, Johnson & Johnson's Tremfya, Biogen's Tysabri and Spinraza, AbbVie and Johnson & Johnson's Imbruvica, Astellas and Pfizer's Xtandi, Novartis' Promacta, Pfizer's Nurtec ODT and Gilead's Trodelvy, among others, and 14 development-stage product candidates. We fund innovation in the biopharmaceutical industry both directly and indirectly - directly when we partner with companies to co-fund late-stage clinical trials and new product launches in exchange for future royalties, and indirectly when we acquire existing royalties from the original innovators. Our industry leading royalty portfolio and capital-efficient business model drives our compounding growth. We have a focused strategy of actively identifying and tracking the development and commercialization of important new therapies, which allows us to move quickly to make acquisitions when opportunities arise. With a deep and experienced team of investment professionals, an exhaustive due diligence process and a focus on high-quality therapies that address significant unmet patient need, we sustain attractive returns above our cost of capital, which in turn propels our compounding growth. Our unique business model enables us to benefit from many of the most attractive characteristics of the biopharmaceutical industry, includi

View Full Filing

View this 10-K filing on SEC EDGAR